The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Probing the links between in vitro potency, ADMET and physicochemical parameters
Open accessAbstract
A common underlying assumption in current drug discovery strategies is that compounds with higher in vitro potency at their target(s) have greater potential to translate into successful, low-dose therapeutics. This has led to the development of screening cascades with in vitro potency embedded as an early filter. However, this approach is beginning to be questioned, given the bias in physicochemical properties that it can introduce early in lead generation and optimization, which is due to the often diametrically opposed relationship between physicochemical parameters associated with high in vitro potency and those associated with desirable absorption, distribution, metabolism, excretion and toxicity (ADMET) characteristics. Here, we describe analyses that probe these issues further using the ChEMBL database, which includes more than 500,000 drug discovery and marketed oral drug compounds. Key findings include: first, that oral drugs seldom possess nanomolar potency (50 nM on average); second, that many oral drugs have considerable off-target activity; and third, that in vitro potency does not correlate strongly with the therapeutic dose. These findings suggest that the perceived benefit of high in vitro potency may be negated by poorer ADMET properties.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Self-citationGoh, K.-I., Cusick, M. E., Valle, D., Childs, B., Vidal, M., & Barabási, A.-L. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701361104 · Cited by 3,242
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Ligand efficiency: a useful metric for lead selection
Hopkins, A. L., Groom, C. R., & Alex, A. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03069-7 · Cited by 1,846
Yıldırım, M. A., Goh, K.-I., Cusick, M. E., Barabási, A.-L., & Vidal, M. (2007) · Nature Biotechnology · doi:10.1038/nbt1338 · Cited by 1,708
Cited by
Discovery and resupply of pharmacologically active plant-derived natural products: A review
Atanasov, A. G., Waltenberger, B., Pferschy-Wenzig, E.-M., Linder, T., Wawrosch, C., Uhrin, P., Temml, V., Wang, L., Schwaiger, S., Heiss, E. H., et al. (2015) · Biotechnology Advances · doi:10.1016/j.biotechadv.2015.08.001 · Cited by 2,904
A comprehensive map of molecular drug targets
Santos, R., Ursu, O., Gaulton, A., Bento, A. P., Donadi, R. S., Bologa, C. G., Karlsson, A., Al-Lazikani, B., Hersey, A., Oprea, T. I., et al. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.230 · Cited by 2,427
Self-citationQuantifying the chemical beauty of drugs
Bickerton, G. R., Paolini, G. V., Besnard, J., Muresan, S., & Hopkins, A. L. (2012) · Nature Chemistry · doi:10.1038/nchem.1243 · Cited by 2,242
Diagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
An analysis of the attrition of drug candidates from four major pharmaceutical companies
Waring, M. J., Arrowsmith, J., Leach, A. R., Leeson, P. D., Mandrell, S., Owen, R. M., Pairaudeau, G., Pennie, W. D., Pickett, S. D., Wang, J., et al. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4609 · Cited by 1,450
The role of ligand efficiency metrics in drug discovery
Hopkins, A. L., Keserü, G. M., Leeson, P. D., Rees, D. C., & Reynolds, C. H. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4163 · Cited by 1,181
Daina, A., Michielin, O., & Zoete, V. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500467k · Cited by 974
The influence of lipophilicity in drug discovery and design
Arnott, J. A., & Planey, S. L. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.714363 · Cited by 868
Meanwell, N. A. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200211v · Cited by 620
Kibble, M., Saarinen, N., Tang, J., Wennerberg, K., Mäkelä, S., & Aittokallio, T. (2015) · Natural Product Reports · doi:10.1039/c5np00005j · Cited by 489
Polypharmacology – Foe or Friend?
Peters, J.-U. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400856t · Cited by 465
Finding the sweet spot: the role of nature and nurture in medicinal chemistry
Hann, M. M., & Keserü, G. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3701 · Cited by 411
In silico ADME/T modelling for rational drug design
Wang, Y., Xing, J., Xu, Y., Zhou, N., Peng, J., Xiong, Z., Liu, X., Luo, X., Luo, C., Chen, K., et al. (2015) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583515000190 · Cited by 367
Rational Approaches to Improving Selectivity in Drug Design
Huggins, D. J., Sherman, W., & Tidor, B. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm2010332 · Cited by 367
Molecular obesity, potency and other addictions in drug discovery
Hann, M. M. (2011) · MedChemComm · doi:10.1039/c1md00017a · Cited by 363
Systems Pharmacology: Network Analysis to Identify Multiscale Mechanisms of Drug Action
Zhao, S., & Iyengar, R. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134520 · Cited by 358
Natural products for human health: an historical overview of the drug discovery approaches
Bernardini, S., Tiezzi, A., Laghezza Masci, V., & Ovidi, E. (2018) · Natural Product Research · doi:10.1080/14786419.2017.1356838 · Cited by 355
Lipophilic Efficiency as an Important Metric in Drug Design
Johnson, T. W., Gallego, R. A., & Edwards, M. P. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00077 · Cited by 349
On the Promise of Photopharmacology Using Photoswitches: A Medicinal Chemist’s Perspective
Fuchter, M. J. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00629 · Cited by 343
The significance of acid/base properties in drug discovery
Manallack, D. T., Prankerd, R. J., Yuriev, E., Oprea, T. I., & Chalmers, D. K. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35348b · Cited by 329
Zhu, T., Cao, S., Su, P.-C., Patel, R., Shah, D., Chokshi, H. B., Szukala, R., Johnson, M. E., & Hevener, K. E. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301916b · Cited by 313
Young, R. J., Green, D. V. S., Luscombe, C. N., & Hill, A. P. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.06.001 · Cited by 311
Structure-based drug screening for G-protein-coupled receptors
Shoichet, B. K., & Kobilka, B. K. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.03.007 · Cited by 294
Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update
Tadesse, S., Caldon, E. C., Tilley, W., & Wang, S. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01469 · Cited by 276
Schneider, M., Radoux, C. J., Hercules, A., Ochoa, D., Dunham, I., Zalmas, L.-P., Hessler, G., Ruf, S., Shanmugasundaram, V., Hann, M. M., et al. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00245-x · Cited by 273
Lagorce, D., Douguet, D., Miteva, M. A., & Villoutreix, B. O. (2017) · Scientific Reports · doi:10.1038/srep46277 · Cited by 266
Liang, X., Li, H., & Li, S. (2014) · Molecular BioSystems · doi:10.1039/c3mb70507b · Cited by 263
Early pharmaceutical profiling to predict oral drug absorption: Current status and unmet needs
Bergström, C. A. S., Holm, R., Jørgensen, S. A., Andersson, S. B. E., Artursson, P., Beato, S., Borde, A., Box, K., Brewster, M., Dressman, J., et al. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.10.015 · Cited by 257
Bhattacharya, S. K., Andrews, K., Beveridge, R., Cameron, K. O., Chen, C., Dunn, M., Fernando, D., Gao, H., Hepworth, D., Jackson, V. M., et al. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400473x · Cited by 73
How do metabolites differ from their parent molecules and how are they excreted?
Kirchmair, J., Howlett, A., Peironcely, J. E., Murrell, D. S., Williamson, M. J., Adams, S. E., Hankemeier, T., van Buren, L., Duchateau, G., Klaffke, W., et al. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci300487z · Cited by 43
Which three-dimensional characteristics make efficient inhibitors of protein–protein interactions?
Kuenemann, M. A., Bourbon, L. M. L., Labbé, C. M., Villoutreix, B. O., & Sperandio, O. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500487q · Cited by 42
Metadata
- Authors
- Gleeson, M. P., Hersey, A., Montanari, D., & Overington, J.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-03
- Volume
- 10
- Issue
- 3
- Pages
- 197-208
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2083354933
- Cited by
- 503
- References
- 58
- FWCI
- 3.61
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.